<DOC>
	<DOCNO>NCT00180869</DOCNO>
	<brief_summary>There evidence suggest red blood cell concentrate ( RBC ) transfusion may immunomodulatory effect . The aim randomize single-center trial compare immune response patient undergo cancer surgery give either unmodified RBC ( UN-RBC ) leuko-reduced RBC ( LR-RBC ) transfusion perioperatively .</brief_summary>
	<brief_title>Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion Cancer Patients</brief_title>
	<detailed_description>This single-center study conduct compare effect peroperative transfusion allogeneic unmodified RBC ( UN-RBC ) versus leuko-reduced RBC ( RED-RBC ) recipient immunity . Patients undergo cancer surgery randomly assign peroperatively receive UN-RBC RED-RBC . Groups stratify age , sex , tumor characteristic , prior transfusion prior cancer treatment . Blood sample collect anesthesia ( d0 ) day 3 , 7 , 14 , 28 transfusion/surgery analyze complete cell blood count , lymphocyte subset , cytokine production ( IL4 , IL10 , IFNgamma , IL12 ) , T-cells repertoire ( TCR ) analysis detection circulate donor cell . Main study endpoint influence treatment arm IL4/IFNgamma ratio . The effect transfusion type give biological parameter also test ( peripheral blood mononuclear cell phenotyping ( PBMC ) , cytokine production stimulate PBMC , T cell repertoire analysis microchimerism assessment ) .</detailed_description>
	<criteria>Surgery cancer transfusion surgery risk great 30 % Surgery curative intent Written inform consent contraindication use allogeneic unmodified red blood cell concentrate antiRBC and/or antiHLA and/or antigranulocyte alloimmunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>cancer</keyword>
	<keyword>peroperative transfusion</keyword>
	<keyword>allogeneic red blood cell concentrate</keyword>
	<keyword>leuko-reduced red blood cell concentrate</keyword>
</DOC>